Sandoz Biosimilars Strategy: Capturing Market O...

By HEOR Staff Writer

January 23, 2026

Sandoz's Strategic Momentum in Biosimilars and Generics Sandoz's biosimilars strategy, as highlighted during the company's presentation at the 44th Annual J.P. Morgan Healthcare...
Navigating Economic Resilience Through Life Sciences Investment
Epidyolex Spending in Portugal Exceeds €3 Million Amid Regulatory Delays
Empowering Leaders at the Global Pharma Executive Course: Navigating Industry...
INFARMED Leadership Appointments: A New Era in Health Regulation and Expertise
Provisional Agreement on EU Pharmaceutical Reform: Boosting Innovation and Co...
Advancing EU Health Technology Assessment: Key Priorities in the HTACG Draft ...
WHO Guidelines Set New Standard for GLP-1 Obesity Therapies in Adults
Biomanufacturing Excellence Act: Strengthening U.S. Biopharmaceutical Manufac...
Enhancing Efficiency in FAST-EU Clinical Trials: A New Era for Biomedical Res...
Patient-Reported Outcomes Trends in Clinical Trials: Insights from 2008-2023
Koselugo EU Approval: A Milestone in Treating Plexiform Neurofibromas for Adu...
Medical Schemes Affordability Crisis: Insights from the CMS Annual Report 202...